(5R)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione | 185428-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (5R)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
• 英文别名: (5R)-5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• CAS: 185428-18-6
• 化学式: C₂₀H₁₉N₃O₄S
• 分子量: 397.455
• InChiKey: XMSXOLDPMGMWTH-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Combination treatment for diabetes mellitus
  申请人：Nycomed GmbH

  公开号：EP2213289A1

  公开（公告）日：2010-08-04

  The invention relates to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.

  本发明涉及(2R,4aR,10bR)-6-(2,6-二甲氧基吡啶-3-基)-9-乙氧基-8-甲氧基-1,2,3,4,4a,10b-六氢菲啶-2-醇与其他活性化合物的组合，用于治疗 2 型和/或 1 型糖尿病。
• COMBINATION TREATMENT FOR DIABETES MELLITUS
  申请人：KLEIN Thomas

  公开号：US20120129817A1

  公开（公告）日：2012-05-24

  The subject matter of this application is directed to combinations of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol with other active compounds for the treatment of diabetes mellitus type 2 and/or type 1.
• 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
  申请人：DeuteRx, LLC

  公开号：US20180125827A1

  公开（公告）日：2018-05-10

  The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating compounds, which are preferably in enantiopure form.